Leitat Technological Center has patented 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain, hyperalgesia, depression, anxiety and attention deficit hyperactivity disorder (ADHD).